新华制药(00719.HK)皮肤黏膜过敏仿制药通过国家药监局一致性评价
山东新华制药股份(00719.HK)公布,公司近日收到国家药品监督管理局核准签发的盐酸苯海拉明片(25mg)《药品补充申请批准通知书》,该产品通过仿制药质量和疗效一致性评价。公司成为国内盐酸苯海拉明片(25mg)第二家通过仿制药一致性评价的企业。
盐酸苯海拉明片为抗过敏类非处方药品,是医保工伤用药,用於皮肤黏膜的过敏,如荨麻疹、过敏性鼻炎、皮肤瘙痒症、药疹,对虫咬症和接触性鼻炎也有效;该产品亦可用於预防和治疗晕动病,有较强的镇吐作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.